Nano-X Imaging Ltd (NNOX) 2023 Q3 法說會逐字稿

Good day and thank you for standing by, and welcome to the Neenah XQ. three 2023 earnings conference call. At this time, all participants are on a listen-only mode. At the speakers' presentation, there will be a question and answer session to ask a question. During that session, you'll need to press star one one on your phone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one. Again. Please be advised that today's conference is being recorded, and I would now like to hand the conference over to your speaker today, Mr. Mike Cavanagh, Investor Relations. Sir, please go ahead.

美好的一天，感謝您的支持，歡迎來到 Neenah XQ。三場 2023 年收益電話會議。此時，所有參與者都處於僅監聽模式。在演講者的演講中，將有一個問答環節來提出問題。在此會話期間，您需要在手機上按星號鍵。然後您將聽到一條自動訊息，建議您舉手。若要撤回您的問題，請按星號一一。再次。請注意，今天的會議正在錄製中，我現在想將會議交給今天的發言人，投資者關係部的邁克·卡瓦納先生。先生，請繼續。

Good afternoon, and thank you for joining us today. Earlier today, Nanox imaging limited release financial results for the quarter ended September 30th, 2023. The release is currently available on the Investors section of the company's website, Erez Meltzer, Chief Executive Officer, and Ron Daniel, Chief Financial Officer, will host this morning's call.

下午好，感謝您今天加入我們。今天早些時候，Nanox Imaging Limited 發布了截至2023 年9 月30 日的季度財務業績。新聞稿目前可在公司網站的投資者部分查看，首席執行官Erez Meltzer 和首席財務官Ron Daniel 將主持本次會議早上的電話。

Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the Company's financial results, research and development, manufacturing in commercialization activities, regulatory process operations, and other matters. These statements are subject to risks, uncertainties and assumptions that are based on management's current expectations as of today and may not be updated in the future. Therefore, these statements should not be relied upon as representing the Company's views as of any subsequent date.

在我們開始之前，我想提醒大家，管理層將在這次電話會議中發表聲明，其中包括有關公司財務業績、研發、商業化活動製造、監管流程運營和其他事項的前瞻性聲明。這些陳述受到風險、不確定性和假設的影響，這些風險、不確定性和假設是基於管理層截至目前的當前預期，未來可能不會更新。因此，這些陳述不應被視為代表公司在任何後續日期的觀點。

Factors that may cause such a difference include, but are not limited to those described in the Company's filings with the Securities and Exchange Commission. Management will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of each non-GAAP financial measure to the nearest GAAP financial measure is provided in the company's press release issued today. The non-GAAP financial measures include non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other expenses and non-GAAP gross loss per share.

可能導致這種差異的因素包括但不限於公司向美國證券交易委員會提交的文件中所述的因素。管理階層也會參考某些非公認會計準則財務指標，向投資者提供更多資訊。該公司今天發布的新聞稿中提供了每項非公認會計原則財務指標與最接近的公認會計原則財務指標的調節表。非 GAAP 財務指標包括非 GAAP 普通股淨虧損、非 GAAP 收入成本、非 GAAP 毛利、非 GAAP 毛利率、非 GAAP 研發費用、非 GAAP 銷售和行銷費用、非GAAP 一般和管理費用、非GAAP 其他費用以及非GAAP 每股毛虧損。

With that, I'd now like to turn the call over to Eric Meltzer.

現在，我想將電話轉給 Eric Meltzer。

Thanks, Mike. And as always, thank you all for joining us today for our financial results call and corporate update. As previously noted, we have intensified our efforts and focus on the U.S. market to jumpstart our commercialization efforts in the region to support these important efforts. Our team and I have increased our presence in the United States over the last few months, and I'm currently in the U.S. We have engaged in discussions with potential customers, clinical partners, particularly U.S. health care sector professionals, focusing on reimbursement and medical workflow and other key stakeholders. We end to expedite the implementation of our commercial infrastructure and advance our future strategic plans.

謝謝，麥克。一如既往，感謝大家今天參加我們的財務業績電話會議和公司最新動態。如前所述，我們加強了力度，重點關注美國市場，以啟動我們在該地區的商業化工作，以支持這些重要的努力。在過去的幾個月裡，我們和我的團隊增加了在美國的業務，我目前在美國。我們與潛在客戶、臨床合作夥伴，特別是美國醫療保健部門的專業人士進行了討論，重點是報銷和醫療工作流程和其他關鍵利害關係人。我們最終將加快商業基礎設施的實施並推進我們未來的策略計劃。

Moving to the recent developments in deployments, I am pleased to announce that we have established the first US-based commercial site and demonstration center for the Nanox, ARC, which is part of our initial wave in the U.S. and Nanox. Arc system has been installed in the New Jersey based imaging center, which marks the beginning of Nanox commercial expansion into the U.S. market. The system passed all necessary tests conducted by licensed and certified physicians and maybe like the comments scanning of patients to acquire medical imaging using the Nanox, ARC, a stationary x-ray system intended to produce 3D tomo graphic images of the MSK system. The clinic staff will manage the operational, professional and administrative services allocating human resources and equipment for the efficient operation of Nanox system in the imaging center. The center will also serve as the demonstration center for our medical professionals, offering them an opportunity to familiarize himself with the system and facilitate the implementation process. More updates on the progress on installments in the US are expected on the investor day on December fourth, we are enhancing our US sales and service team, and I'm happy to announce we have signed an agreement with six to six and national healthcare technology and equipment management company. They will provide services for the Nanox ARC, including warehousing, installation, training, maintenance and customer support, headquartered in Boca Raton, Florida six to six offers tools necessary for imaging centers to achieve maximum uptime and maintain better patient care. Six to six has expertise in modalities and medical imaging equipment and provides customized services tailored to their clients' needs for their eyes. Those 1348 and 85 certification national footprint and over 160 field service engineers. They are an ideal company to partner with and as we ramp up our commercialization efforts in the US. In addition to them supporting installations, maintenance and services in the field, we intend to install an ARC system in their suburban Atlanta, six to six imaging Academy. We're trained in demonstration purposes.

談到最近的部署進展，我很高興地宣布，我們已經為 Nanox ARC 建立了第一個位於美國的商業站點和演示中心，這是我們在美國和 Nanox 的初始浪潮的一部分。 Arc系統已安裝在位於新澤西州的成像中心，這標誌著Nanox商業擴張進入美國市場的開始。該系統通過了由有執照和認證的醫生進行的所有必要測試，可能就像使用Nanox、ARC（一種固定X 射線系統，旨在生成MSK 系統的3D 斷層圖像）對患者進行掃描以獲得醫學成像一樣。診所工作人員將管理營運、專業和行政服務，分配人力資源和設備，以確保影像中心 Nanox 系統的高效運作。該中心也將作為我們醫療專業人員的示範中心，為他們提供熟悉系統並促進實施過程的機會。預計在12 月4 日的投資者日會有更多關於美國分期付款進展的更新，我們正在增強我們的美國銷售和服務團隊，我很高興地宣布我們已經與六對六和國家醫療保健技術簽署了協議和設備管理公司。他們將為總部位於佛羅裡達州博卡拉頓的Nanox ARC 提供服務，包括倉儲、安裝、培訓、維護和客戶支持，六到六家為成像中心提供必要的工具，以實現最長的正常運行時間並維持更好的患者護理。六到六擁有模式和醫學影像設備方面的專業知識，並根據客戶的眼睛需求提供客製化服務。擁有 1348 個和 85 個認證國家足跡以及 160 多名現場服務工程師。當我們加強在美國的商業化時，他們是理想的合作夥伴。除了在現場支援安裝、維護和服務之外，我們還打算在亞特蘭大郊區的六到六所成像學院安裝 ARC 系統。我們接受了演示目的的訓練。

Turning now to our deployment efforts in the rest of the world outside of the key US market, we have begun to generate revenues from hardware deployment in Africa While these revenues are currently small, they are growing. Additionally, as previously announced and Alex, our journey has been installed in the University of Ghana Medical Center limited EGMC. one of the largest and most advanced hospitals in Ghana. We are pleased to announce that our local partner has obtained approval from the Ghana, food and drug authority. The G. FDA and it will soon be operational for clinical scanning of patients. In the meanwhile, we have received an order for additional units in Ghana. We're also actively working on establishing a presence in Latin America. One of our distribution partners is in the process of securing an import license for Nanox, Arques as well as laying the groundwork or demonstration center that potential location for the demo site in Boston College Hospital offerings is the very space and expertise both on the non-op side, we will provide further detail on these developments as we make substantial progress.

現在轉向我們在美國主要市場之外的世界其他地區的部署工作，我們已經開始從非洲的硬體部署中獲得收入，雖然這些收入目前很小，但正在成長。此外，正如 Alex 之前宣布的那樣，我們的旅程已安裝在加納大學醫學中心有限公司 EGMC 中。加納最大、最先進的醫院之一。我們很高興地宣布，我們的當地合作夥伴已獲得加納食品藥物管理局的批准。 G. FDA 及其很快將用於對患者進行臨床掃描。同時，我們收到了在加納購買更多設備的訂單。我們也積極致力於在拉丁美洲建立業務。我們的分銷合作夥伴之一正在獲得 Nanox、Arques 的進口許可證，並正在奠定基礎或演示中心，波士頓學院醫院產品中演示站點的潛在位置正是非非領域的空間和專業知識。另一方面，隨著我們取得實質進展，我們將提供有關這些進展的進一步細節。

Turning to our OEM initiatives to meet the anticipated demand of our system. As previously announced, we entered into original equipment manufacturing agreement with Mark's, a leading global manufacturers of imaging components based in Utah. We have since held a formal partnership kickoff meetings, Exalytics headquarters in Salt Lake City. What are the company's executive and technical teams came together to continue final to design efforts and map out all the road maps towards production expanding on our OEM related activity. We are currently engaged with an industrial imaging equipment manufacture on a chip development and manufacturing program we expect to formalize by the year end to ensure an adequate future supply of chips. Additionally, our collaboration with the US government agency exploring none of our technology for use in security screening application is advancing with the acquisition of tubes and further testing and evaluation. Finally, a leading global medical technology company has purchased amateurs for internal testing and application development project. We have not in our regulatory path despite our efforts to gain regulatory approval in a number of markets across the world. Sometimes our grand total Ford receives slower than we would like in some instances, such as with the FDA in the U.S., each jurisdiction has its independent set of regulations contributing to the complexity of the process. We are diligently navigating these challenges, prioritizing Swift approvals while ensuring accuracy and regulatory compliance. Nonetheless, we have not stopped pushing ahead with our regulatory efforts, which continue to be of paramount importance to NetIQ's. As previously communicated, we partnered with ESI. Group, an incredible Notified Body based on the United Kingdom for eventual CE Marking review and approval. I'm happy to announce that we have submitted our technical file for obtaining the CE mark DSI's formulary review will begin in the first quarter of 2024 according to the plan time line. And I look forward to providing updates upon the conclusion of this process.

轉向我們的 OEM 計劃來滿足我們系統的預期需求。正如先前宣布的，我們與 Mark's 簽訂了原始設備製造協議，Mark's 是一家位於猶他州的全球領先的成像組件製造商。此後，我們在位於鹽湖城的 Exalytics 總部舉行了正式的合作夥伴啟動會議。公司的執行和技術團隊齊心協力，繼續進行最終設計工作，並製定了擴大 OEM 相關活動生產的所有路線圖。我們目前正在與工業成像設備製造商合作進行晶片開發和製造計劃，我們預計將在年底前正式實施，以確保未來有充足的晶片供應。此外，我們與美國政府機構的合作正在隨著管材的採購以及進一步的測試和評估而取得進展，該機構沒有探索我們的技術用於安全檢查的應用。最後，一家全球領先的醫療技術公司購買了業餘愛好者進行內部測試和應用開發專案。儘管我們努力在全球許多市場獲得監管批准，但我們還沒有走上監管之路。有時，在某些情況下，我們福特的總計接收速度比我們希望的要慢，例如美國 FDA，每個司法管轄區都有其獨立的一套法規，這導致了流程的複雜性。我們正在努力應對這些挑戰，優先考慮 Swift 批准，同時確保準確性和合規性。儘管如此，我們並沒有停止推進監管工作，這對 NetIQ 仍然至關重要。正如之前所傳達的，我們與 ESI 合作。 Group，一家總部位於英國的令人難以置信的公告機構，負責最終的 CE 標誌審查和批准。我很高興地宣布，我們已經提交了獲得 CE 標誌的技術文件。DSI 的規定審查將於 2024 年第一季按照計劃時間表開始。我期待著在這一過程結束後提供最新資訊。

We have also made substantial progress in our home market, Israel, the Medical Device division of the Ministry of cells known as MRAMAR. is the regulatory body that oversees medical devices. On November 22nd, 2023 Nanox. Arc received our approval from the Israeli Ministry of Health, and it is now registered as a medical device and base oil market. Following this approval from the Israeli Ministry of Health granted Nano-X ARC, a free sales certificate, which is a requirement for regulatory submission in some markets.

我們在國內市場以色列也取得了實質進展，細胞部的醫療器材部門稱為 MRAMAR。是監督醫療器材的監管機構。 2023 年 11 月 22 日 Nanox。 Arc獲得了以色列衛生部的批准，現已註冊為醫療器材和基礎油市場。繼以色列衛生部批准後，Nano-X ARC 獲得了免費銷售證書，這是某些市場監管提交的要求。

Turning to our clinical efforts, as previously disclosed, the second phase of collecting clinical sample images of multiple human body have not optimized for the Nanox. Our systems deployed at Shamir hospital and Israeli is continuing. Additionally, Nanox reach an agreement with billings in the hospital as part of the club retail services, the largest health service organization in Israel and one of the largest in the world. According to this agreement, a human trial designed to assess diagnostic capabilities of genomics, art in detecting chest and lung diseases will be launch and the balance of hospital all required Israeli Ministry of Health approval and institutional Ethics Committee has been obtained and the trial is scheduled to commence by the end of 2023.

談到我們的臨床工作，如同先前所揭露的，收集多個人體臨床樣本影像的第二階段尚未針對 Nanox 進行最佳化。我們在沙米爾醫院和以色列部署的系統仍在繼續。此外，Nanox 與醫院的 Billings 達成協議，作為俱樂部零售服務的一部分，該俱樂部是以色列最大的健康服務組織，也是世界上最大的健康服務組織之一。根據該協議，將啟動一項人體試驗，旨在評估基因組學的診斷能力、檢測胸部和肺部疾病的技術，醫院所需的所有準備工作均已獲得以色列衛生部和機構倫理委員會的批准，並已安排試驗將於 2023 年底開始。

Now I would like to provide an update on our Nanox I. a business segment. We generated $141,000 in revenue during this quarter and one, we'll review it in more detail shortly.

現在我想介紹一下我們的 Nanox I.a 業務部門的最新情況。我們在本季創造了 141,000 美元的收入，我們很快就會對其進行更詳細的審查。

At the end of the quarter, we announced compelling study results, which demonstrated that annex AI. product phone at approximately 60% of patients unknowingly had moderate to severe level of coronary artery calcium, also known as CAC, a proven indicator of future cardiac events. The study was sponsored by Nanox AI. and conducted by vendors for hospitals utilizing Nanox. A I hope CCS and FDA cleared and CE Marked tool designed specifically for cardiac health assessment, helps CCM solution utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC, potentially offering an early detection mechanism for cardiovascular calcium and presenting cardiac care in other non-op sire news, a five 10 K submission for Nanox. Fatty liver detection, known as health FLD. was submitted in September and is pending FDA five 10 K clearance Health System V is designed to detect early signs of fatty liver diseases from routine tests and update on CT scans, not specifically for broker liver assessments. These updates are highly promising, and I look forward to providing additional updates on dynamics. I noticed our business throughout 2024. Before turning the call over to Ron, I'd like to revisit one of the AI. products agreement that we have announced previously. In mid 2022, we announced a strategic agreement with Spectrum Health now known as CORE, will Health, one of the leading integrated delivery system IDNs to use our AI population health solutions, Kobo management reports that their team has successfully integrated the Nanox, a i-Health CCS solution into their patient care flow, recognizing its significant value in identifying new patients with medium and high calcium level on chest CT scans. We have also received similar positive feedback from another health care system using non-US AI solutions.

在本季末，我們宣布了令人信服的研究結果，證明了人工智慧的附件。大約 60% 的患者在不知情的情況下患有中度至重度冠狀動脈鈣化水平（也稱為 CAC），這是未來心臟事件的一個經過驗證的指標。該研究由 Nanox AI 贊助。由使用 Nanox 的醫院供應商進行。我希望CCS 和FDA 批准並獲得CE 標誌的工具專為心臟健康評估而設計，可幫助CCM 解決方案利用常規胸部CT 掃描的醫學成像數據來自動量化和分析CAC，從而有可能提供心血管鈣的早期檢測機制並在以下情況下提供心臟護理：其他非操作新聞，為 Nanox 提交的 5 篇 10 K 文章。脂肪肝檢測，稱為健康FLD。已於 9 月提交，正在等待 FDA 5 個 10 K 許可 Health System V 旨在透過常規測試和 CT 掃描更新來檢測脂肪肝疾病的早期跡象，而不是專門用於經紀人肝臟評估。這些更新非常有希望，我期待提供更多動態更新。我注意到我們整個 2024 年的業務。在將電話轉給 Ron 之前，我想重新審視其中一個人工智慧。我們先前宣布的產品協議。 2022 年年中，我們宣布與Spectrum Health（現稱為CORE）達成策略協議，將Health（領先的整合交付系統IDN 之一）使用我們的AI 人口健康解決方案，Kobo 管理層報告稱，他們的團隊已成功整合Nanox，這是一個-將 Health CCS 解決方案納入患者護理流程，認識到其在識別胸部 CT 掃描中鈣水平中等和高的新患者方面的重要價值。我們也從另一個使用非美國人工智慧解決方案的醫療保健系統收到了類似的正面回饋。

And with that, I'd like to now turn the call over to Rand Daniel for review our financial results run.

現在，我想將電話轉給蘭德·丹尼爾，以審查我們的財務表現。

Thank you, Eric. We have reported GAAP net loss for the third quarter of 2023 of $21.4 million compared with a net loss of $19.1 million in the third quarter of 2022, which is the comparable period. The aqueous was largely due to a quarter, I will impairment of $7.4 million, an increase of $0.4 million in the sales and marketing expenses, which was offset by a decrease in our general and administration expenses in the amount of $5.6 million.

謝謝你，埃里克。我們報告的 2023 年第三季 GAAP 淨虧損為 2,140 萬美元，而同期 2022 年第三季的淨虧損為 1,910 萬美元。水性損失主要是由於本季減值 740 萬美元，銷售和行銷費用增加 40 萬美元，但一般和管理費用減少 560 萬美元抵消了這一損失。

Our non-GAAP net loss for the third quarter of 2023 was $9.4 million compared with net loss of $8.1 million a net loss for a period. The increase was largely due to an increase of $0.4 and of itself and marketing expenses and $0.1 million in other expense. Revenues for the third quarter of 2023 of our $2.5 billion and growth of $1.7 million on a GAAP basis, revenue for the comparable period, where $2.4 million and graphical, whilst the $1.5 million on a GAAP basis, non-GAAP gross profit for the three months ended September 30th, 2023, was $0.9 million as compared to $1.1 million in the comparable period, which represents a gross profit margin of approximately 37% on a non-GAAP basis for the three months ended September 30, 2023, as compared to 46% on a non-GAAP basis in the comparable period.

我們 2023 年第三季的非 GAAP 淨虧損為 940 萬美元，而同期淨虧損為 810 萬美元。這一增長主要是由於 0.4 美元的增長以及營銷費用和 10 萬美元的其他費用的增加。 2023 年第三季的營收為 25 億美元，以 GAAP 計算成長 170 萬美元，可比期間的營收為 240 萬美元，圖表顯示，而以 GAAP 計算的非 GAAP 毛利為 150 萬美元截至2023 年9 月30 日止三個月的毛利率為90 萬美元，而同期為110 萬美元，這意味著截至2023 年9 月30 日止三個月的毛利率約為37%，而截至2023 年9 月30日止三個月的毛利率為46%。%（以非公認會計原則計算） 可比期間的百分比。

Revenue from teleradiology services for the three months ended September 30, 2023 was $2.2 million with the gross profit of $0.2 million on a GAAP basis as compared to revenue of $2.4 million with a gross profit of $0.6 million on a GAAP basis in the comparable period, which represents a gross profit margins of approximately 11% on a GAAP basis for the three months ended September 30, 2023, as compared to 26% on a GAAP basis in the comparable period.

截至 2023 年 9 月 30 日的三個月遠距放射服務收入為 220 萬美元，以 GAAP 計算毛利為 20 萬美元，而同期收入為 240 萬美元，以 GAAP 計算毛利為 60 萬美元，截至2023年9月30日止三個月，以公認會計原則計算，毛利率約11%，而同期以公認會計原則計算，毛利率為26%。

Non-gaap gross profit of the companies that have ideology benefits for the three months ended September 30, 2023, was $0.8 million compared to $1.2 million of in the comparable period, which represents a gross profit margin of approximately 36% on a non-GAAP basis for the three months and September 30, 2023, as compared to 49% on a non-GAAP basis in the comparable period.

截至2023 年9 月30 日止三個月，具有意識形態優勢的公司的非公認會計原則毛利潤為80 萬美元，而同期的毛利為120 萬美元，按非公認會計原則計算，毛利率約在36%三個月和 2023 年 9 月 30 日的基礎上，相較之下，可比期間的非 GAAP 基礎上的基礎上為 49%。

Decrease in gross profit margin on a GAAP and non-GAAP basis is mainly due to an increase in the cost of the company through our geology due to the decrease in the risk rate and payment of incentive payments, which the company paid to the company that ideologies engaging the ratings during the overnight and weekend shift.

以公認會計原則和非公認會計原則計算的毛利率下降，主要是由於風險率下降和公司向公司支付的激勵金的支付導致公司的地質成本增加。意識形態在夜間和週末輪班期間影響收視率。

During the three months ended September 30, 2023, the company for us to generate revenue for the sales and deployment of its imaging systems, which amounted to $99,000 with a gross profit of $36,000 and a GAAP and non-GAAP basis, which represents a gross profit margins of approximately 37%. On a GAAP and non-GAAP basis, revenue expense from the sales and deployments.

截至 2023 年 9 月 30 日的三個月內，該公司透過銷售和部署其成像系統為我們創造了收入，達到 99,000 美元，毛利為 36,000 美元，按照 GAAP 和非 GAAP 計算，這代表了毛利利潤率約37%。根據公認會計原則和非公認會計原則，銷售和部署產生的收入費用。

Research and development expenses for the first quarter of 2023 were $6.0 million as compared to $6.1 million for the comparable period in 2022, a decrease of $0.1 million of mainly due to a decrease in the cost of labor of $0.6 billion of which are was offset by an increase in the company's development of the art distance expenses in the amount of $0.5 million.

2023 年第一季的研發費用為600 萬美元，而2022 年同期的研發費用為610 萬美元，減少了10 萬美元，主要是由於勞動力成本減少了6 億美元，其中勞動力成本減少了6 億美元，但被公司開發遠距藝術費用增加了50萬美元。

Sales and marketing expenses for the third quarter of 2023 were $1.1 million compared to $0.7 million reported for the comparable period in 2022 to the increase was mainly due to our go-to-market efforts in the US market in anticipation for the soft launch of our products in the US market.

2023 年第三季的銷售和行銷費用為 110 萬美元，而 2022 年同期報告的銷售和行銷費用為 70 萬美元，成長主要是由於我們在美國市場的上市努力，預計我們的軟啟動產品在美國市場。

General and administrative expenses for the third quarter of 2023 were $5.0 million as compared to $10.6 million for the comparable period in 2022 that the credit of $5.6 million was mainly due to a decrease in our legal expenses in the amount of $2.9 million, largely as a result of the finalization of the SEC investigation. A decrease in share-based compensation in the amount of $2.7 million and a decrease in the cost of directors' and officers' liability insurance peer trillion in the amount of $0.3 million.

2023 年第三季的一般及行政費用為 500 萬美元，而 2022 年同期為 1,060 萬美元，貸項 560 萬美元主要是由於我們的法律費用減少了 290 萬美元，主要是由於SEC 調查的最終結果。股票薪酬減少 270 萬美元，董事和高階主管責任保險成本減少 30 萬美元。

Goodwill impairment for the third quarter of 2023 was $7.4 million due to the goodwill impairment related to the teleradiology reporting unit in the amount of $7.0, and then Alex Xie reporting unit in the amount of [$0.4 million], largely due to the increase in the discount rate and management estimates that it will take longer than we originally expected to generate original growth of revenues, gross profit and positive operating cash flow in the AI. and tell our geology business segments.

2023 年第三季的商譽減損為740 萬美元，原因是與遠距放射學報告單位相關的商譽減損金額為7.0 美元，然後Alex Xie 報告單位的商譽減損金額為[40 萬美元]，主要是由於折現率和管理層估計，人工智慧領域實現收入、毛利和正營運現金流的原始成長需要比我們最初預期的時間更長的時間。並告訴我們的地質業務部門。

During the first nine months of 2023, we had that occurred $0.7 million of future government expenses in connection with the SEC investigation. As previously discussed, the company and around project came our Chairman of the Board of Directors and reached a settlement agreement with the SEC. During October 2023, the company paid $650,000 in civil penalties under this agreement.

在 2023 年前 9 個月，我們發現與 SEC 調查相關的未來政府支出為 70 萬美元。正如之前所討論的，該公司和周圍的項目來到了我們的董事會主席並與 SEC 達成了和解協議。 2023 年 10 月期間，該公司根據該協議支付了 65 萬美元的民事罰款。

Turning to our balance sheet. As of September 30, 2023, we had cash, cash equivalents, restricted deposits and marketable securities of approximately $95.6 million and at $3.3 million loan from a bank. We ended the quarter with property and equipment net of $45.1 million. As of September 30, 2023 we have approximately $57.7 million shares outstanding compared to $52.1 million shares outstanding as of December 31, 2022 the increase was mainly due to the sales of approximately $2.1 million shares of our warrants to purchase up to $2.1 million shares in a registered direct offering consideration of the gross profit of $30 million and a net profit of approximately [$20.7 million] and the issuance of approximately 255,000 ordinary shares for the former shareholders of US Rob, under the amendment to the US for our stock purchases previously discussed.+ With that, I will end the call back over to Eric.

轉向我們的資產負債表。截至 2023 年 9 月 30 日，我們擁有約 9,560 萬美元的現金、現金等價物、限制性存款和有價證券，以及銀行的 330 萬美元貸款。本季結束時，我們的財產和設備淨值為 4,510 萬美元。截至2023 年9 月30 日，我們的已發行股票約為5,770 萬美元，而截至2022 年12 月31 日，已發行股票為5,210 萬美元，增加的主要原因是出售了約210 萬美元的認股權證，以購買最多210 萬美元的股票。根據先前討論的美國股票購買修正案，註冊直接發行對價為3000 萬美元的毛利潤和約[2070 萬美元]的淨利潤，並為美國羅布的前股東發行約255,000 股普通股。+ 至此，我將結束通話並轉回給埃里克。

Thank you all. Once again for joining our call today and for your ongoing support of Nellix. We are making significant progress toward deployment of the Nanox, the ARC system that scale in both the U.S. and other markets. And I'm looking forward to our Investor Day next week and ours Q4 update call in early 2020s to Investor Day or meet with the Nanox team.

謝謝你們。再次感謝您今天加入我們的電話會議並感謝您對 Nellix 的持續支持。我們在部署 Nanox（可在美國和其他市場擴展的 ARC 系統）方面取得了重大進展。我期待著下週的投資者日以及 2020 年初的第四季度投資者日更新電話會議或與 Nanox 團隊會面。

While we are in New York area, please contact our Investor Relations partners at ICR. Westlake has a good day. Operator, please open the session to Q&A.

當我們在紐約地區時，請聯繫我們 ICR 的投資者關係合作夥伴。西湖度過了美好的一天。操作員，請開啟問答環節。

Thank you. As a reminder, to ask a question, please press star one one on your phone and wait for your name to be announced to withdraw your question, please press star one one. Again stand by as you compile the Q&A roster. And one moment please for our first question. Our first question will come from Jeff Cohen of Ladenburg Thalmann.

謝謝。提醒一下，要提問，請在手機上按星一一，等待您的名字被宣布，要撤回您的問題，請按星一一。在編制問答名冊時再次做好準備。請稍等一下我們的第一個問題。我們的第一個問題將來自 Ladenburg Thalmann 的 Jeff Cohen。

Good morning, Erez and Ran every year.+ Great manager.+ So a few questions from Merrill Lynch. You spoke about a government agency and some security screening, and this may be a stupid question, but the shelf for people or is it true goods such as luggage?

早上好，Erez 和 Ran 每年。 + 很棒的經理。+ 美林證券問幾個問題。你談到了政府機構和一些安全檢查，這可能是一個愚蠢的問題，但是用於人的貨架還是行李等真正的貨物？

No. We indicated last year, no matter where it's the same. It's the same agency that we acquired. The first one in the first trial was successful. So they now go to the next step. We don't know exactly what's the what's the purpose of the use it.

不會。我們去年就表示過，無論在哪裡都是一樣的。這是我們收購的同一家機構。第一次試驗第一成功。所以他們現在進入下一步。我們並不確切知道使用它的目的是什麼。

Okay, got it. And so can you go back to your submission and notified body, walk us through the time line there as some of the documentation has gone in or will be going in shortly? And what would you anticipate on the time line being that there's some further precedent in the restaurant.

好，知道了。那麼，您能否回到您的提交和公告機構，引導我們了解那裡的時間線，因為一些文件已經進入或即將進入？你對時間軸的預期是，餐廳裡還有一些進一步的先例。

So So in a way, we are kind of ahead of ahead of what we anticipated to do it next year. We have already submitted all the information, all the if the weight goes that that the notified body who opens kind of a window are over a site that you'd say you upload all the information, you know, it's thousands of pages. And then once all the information is on, then you go to some questions, further invest in further visits at the site today or kind of check. And I don't want to give any.

因此，在某種程度上，我們有點領先我們明年的預期。我們已經提交了所有的信息，所有的信息，如果權重是，打開一個窗口的通知機構在一個網站上，你會說你上傳了所有的信息，你知道，它有數千頁。然後，一旦所有資訊都打開，您就會提出一些問題，進一步投資於今天對該網站的進一步訪問或某種檢查。而我什麼也不想給。

You know, we have been saying all the time that regulation is in medical equipment is something that is always challenging and very complicated, and it allows a lot of facets. But but we assume that with the quality of the information and the quality of the of the clinical trials that we have in the with the quality of the (unk), the eyes of the two we passed all of this. It will be real reasonably faster than what ours operate. And I have an estimation, but but I think that it would be better to wait until we get a better clarity winning 2024, we will get it.

你知道，我們一直在說，醫療設備的監管總是充滿挑戰、非常複雜，而且涉及很多方面。但是我們假設，憑藉資訊的品質和臨床試驗的質量，以及（unk）的質量，我們通過了這一切。它將比我們的操作速度真正快得多。我有一個估計，但我認為最好等到 2024 年我們獲得更好的清晰度，我們會得到它。

Okay. Is it safe to say you're hopeful currently that you're going to see you clearance in 2024.

好的。可以肯定地說，您目前希望在 2024 年獲得許可。

As I say from his point of view from, I would say that data, it would be reasonable to say.

正如我所說從他的角度來看，我會說數據，這是有道理的。

Got it. Okay. And then lastly for us, could you go back to on Cervarix facility in Utah and talk about their capabilities there as far as anticipated number of units that could be assembled and produce per month or per quarter or per year.

知道了。好的。最後，您能否回到猶他州的 Cervarix 工廠，談談他們在那裡的能力，以及每月、每季或每年可以組裝和生產的預計數量。

So as you know, Varex is the largest player in tubes for the imaging in the world come from. And I was there a few weeks ago, we had a long day session of the kickoff from both for the future road map of future breakthrough technologies wrote problem aspects for four products and the other thing is the continuous supply. And from from the capacity point of view, they will be able to supply whatever we need going forward. They are not going we're not going to be dependent our volumes. We're going to continue with our strategy to ensure that we have at least two or three suppliers for each one of the components that we have. So this, the tubes will be included and they will be one of the there will be a major supplier, but not the sole supplier.

如您所知，Varex 是世界上最大的成像管製造商。幾週前我在那裡，我們舉行了漫長的一天會議，從未來突破性技術的未來路線圖開始，為四種產品寫了問題方面，另一件事是持續供應。從產能的角度來看，他們將能夠供應我們未來所需的任何東西。他們不會去，我們不會依賴我們的數量。我們將繼續執行我們的策略，以確保我們擁有的每種組件至少有兩到三個供應商。因此，管子將被包括在內，它們將成為主要供應商之一，但不是唯一的供應商。

Okay, perfect retention for us. Thanks for taking the questions.

好的，對我們來說完美的保留。感謝您提出問題。

Thank you for that, Jeff.

謝謝你，傑夫。

Thank you. One moment please, for our next question. Our next question will come from Ross Osborne of Cantor Fitzgerald. Your line is open guys.

謝謝。請稍等一下，我們的下一個問題。我們的下一個問題將來自康托·菲茨杰拉德的羅斯·奧斯本。你們的線路是開放的，夥計們。

Good morning. Congrats on the progress. Thanks for taking the questions. And hope your loved ones and employees are safe as possible. And given the war was just starting off with the New Jersey Imaging Center, which you provide some more color on the types of patients that center manages. And when we take expect the synergy to be up and running at scale Okay, up and running right now.

早安.祝賀取得的進展。感謝您提出問題。並希望您的親人和員工盡可能安全。鑑於新澤西影像中心的戰爭剛剛開始，您為該中心管理的患者類型提供了更多資訊。當我們期望協同效應能夠大規模啟動並運行時，好的，現在就啟動並運行。

The second is at scale right now is what we are focusing on and we do hope that that it will be, I would say we'll be in scale, probably the by the end of the year or beginning of the next year. January, we are planning to open the site for demos for people who would be willing to visit and see some I would say also that this will be another solution that we have managed to to create a sense of right now in Israel, although we do business business as usual and everything that we're planning we're doing and some people or some visits that were supposed to come to Israel have postponed their visit. So they will be able to come to come to New Jersey and come and see and we're going to be there. It's going to be serve as the, you know, six to six for example, the one that we mentioned already, where part of the installations that we have there. So it's kind of fast friendly environments for us to ensure that we're going to take all the benefits of the proof of concept, both for demonstration purposes and for operational. We mentioned also that as we speak, we are making the next site installations before the year before the end of the year. So basically, the of the go-to-market strategy and the go-to-market action plan in the U.S. is up and running. We're building the team. We signed the agreement, we are aiming to scan the first U.S. patients patients in the coming days. So we have all the necessary approvals. But the this is something that we're planning do we have managed to get almost all the certification and finding that physics that the game to be there enable us to commence the scanning of patients, et cetera. So it's good or we are happy with it.

第二個是我們現在關注的重點，我們確實希望，我想說的是，我們會規模化，可能是在今年年底或明年初。一月份，我們計劃向願意訪問並觀看一些演示的人開放該網站，我還要說，這將是我們現在設法在以色列營造一種感覺的另一個解決方案，儘管我們確實這樣做了一切照常進行，我們正在計劃要做的一切，一些本來應該來以色列的人或一些訪問已經推遲了。所以他們將能夠來新澤西州看看，我們也會在那裡。它將作為，例如，我們已經提到的六到六個，我們在那裡安裝的一部分。因此，這對我們來說是一種快速友好的環境，可以確保我們能夠充分利用概念驗證的所有優勢，無論是出於演示目的還是為了操作目的。我們也提到，正如我們所說，我們將在年底前進行下一次現場安裝。因此，基本上，美國的上市策略和上市行動計劃已經啟動並運行。我們正在建立團隊。我們簽署了協議，我們的目標是在未來幾天內對第一批美國患者進行掃描。所以我們擁有所有必要的批准。但這是我們正在計劃的事情，我們是否已經設法獲得幾乎所有認證並發現遊戲的物理原理使我們能夠開始對患者進行掃描等等。所以這很好，或者我們對此感到滿意。

Sounds great. And then turning to Morocco, can you discuss the level of utilization in terms of scans per day or your metric of choice there at the moment systems you have delivered today.

聽起來很棒。然後轉向摩洛哥，您能否討論一下每天掃描的利用率等級或您今天交付的系統目前選擇的指標。

And I think that this is something that we will share. We will shed some light on the Investors Day next week.

我認為這是我們將分享的事情。我們將在下週的投資者日公佈一些情況。

I guess Fair enough leading towards that by name.

我想透過名字就可以很公平地實現這一點。

But baseball, you basically right now it's in line of I would say that the feed slate is in line with what we anticipated.

但是棒球，現在基本上是符合我想說的，提要板符合我們的預期。

It is starting to think about next year, given some of your recent manufacturing agreements, when should we expect an inflection in system deployments and expansion into new geographies outside of Morocco, Ghana and Nigeria. Just trying to get an understanding of system placement cadence for 2024, given you're now commercial and have contracts with these geographies for one hundreds of systems.

鑑於你們最近的一些製造協議，我們開始考慮明年，我們何時應該期待系統部署和擴展到摩洛哥、加納和尼日利亞以外的新地區的變化。鑑於您現在已經商業化並與這些地區簽訂了數百個系統的合同，我只是想了解 2024 年的系統部署節奏。

So you asked about the next. I think that we've indicated already working with the family to work to fulfill the, um, the orders that we had originally mentioned, the agreements that we have in each one of them. We are making progress in terms of the regulation approvals. So part of them will be other countries in Africa are part of them will be in Latin America and part of them will be in Asia and and European countries, which are not dependent on on yield. So that's that's that's the plan so far, we've put it's all depend on the process and the progress that we made with the regulation approvals. But this is also something that we will we will give some more color on next week.

所以你問了下一個。我認為我們已經表示已經與家人合作，努力履行我們最初提到的命令，以及我們在每項命令中達成的協議。我們在監管審批方面正在取得進展。因此，其中一部分將在非洲其他國家，一部分將在拉丁美洲，一部分將在亞洲和歐洲國家，這些國家不依賴產量。這就是到目前為止的計劃，我們認為這一切都取決於我們在監管批准方面取得的流程和進展。但這也是我們將在下週提供更多色彩的事情。

Thank you again. One moment please for our next question. Our next question will come from Ben Haynor of the Alliance Capital Partners. Your line is open.

再次感謝你。請稍等一下我們的下一個問題。我們的下一個問題將來自 Alliance Capital Partners 的 Ben Haynor。您的線路已開通。

Good day, gentlemen. Can you hear me okay.

美好的一天，先生們。你聽得到我說話嗎？

Yet another Good morning.

又一個早安。

Great.

偉大的。

So I was just looking to understand the next ARC revenue a little bit better for the quarter. It sounds like some of that came from sales. If you give me a sense of or give us a sense of how how much capital revenue was included in there. And then would you expect the revenue that you're generating out of Africa from these systems to grow from the Q3 level going forward?

所以我只是想更了解本季 ARC 的下一個收入。聽起來其中一些來自銷售。如果你讓我了解或讓我們了解其中包含了多少資本收入。那麼您是否預計透過這些系統在非洲產生的收入將從第三季的水平開始成長？

Yes.

是的。

So Tom, you referred to the 19 $99,000 that we recorded in the quarter, correct?

湯姆，您提到了我們在本季記錄的 19 美元 99,000 美元，對嗎？

Correct.

正確的。

Yes. Okay. So those are actually stems from the sales revenue from our two D imaging systems. There are the split is between three countries.

是的。好的。所以這些其實是來自我們的兩台D成像系統的銷售收入。三個國家之間存在分歧。

The first one is coming from. The second one is Morocco and the other one is Ghana. We're talking of a few of a few a few systems in each region and some of the revenue comes from the sales of those units and the other one from the usage of those units.

第一個來自。第二個是摩洛哥，另一個是加納。我們討論的是每個地區的幾個系統，其中一些收入來自這些設備的銷售，另一部分來自這些設備的使用。

But okay.

但好吧。

This is I guess what I'm getting at. That's helpful. But what I'm getting at is would you expect the revenue from a system to tick up from the 9,000 level, the ones that are currently in those geographies, then everybody said generally?

這就是我想我要表達的意思。這很有幫助。但我的意思是，您是否期望系統的收入從 9,000 的水平（目前在這些地區的水平）上升，然後每個人都普遍這麼說？

Yes, because some of those on a provided for demo and training purposes, and we expect that those units will become commercial yield, of course, we'll add more and more units on those ones. And of course, we expect to start generating revenue from the Arca for the revenue from the ARC systems itself in those regions.

是的，因為其中一些是用於演示和培訓目的，我們預計這些單位將成為商業收益，當然，我們將在這些單位上添加越來越多的單位。當然，我們希望開始透過 Arca 為這些地區的 ARC 系統本身帶來收入。

In the US itself in these units.

在美國本身就有這些單位。

By the way, I would say that the numbers of scans per day where they are operational is actually our numbers are exceeding our original expectations.

順便說一句，我想說的是，他們每天的掃描數量實際上是我們的數字超出了我們最初的預期。

Okay. That's good to hear and helpful. And then just on the on the various agreements, I was curious about the minimal annual amount on that. Is that something that's relatively easy to achieve? Or is it that kind of a small fraction of the anticipated the realization? Or what's the right way to think about that?

好的。這很高興聽到並且很有幫助。然後就各種協議而言，我很好奇每年的最低金額。這是相對容易實現的事情嗎？或者這只是預期實現的一小部分？或思考這個問題的正確方法是什麼？

From my side? profitability are from our point of view.

從我這邊？獲利能力是從我們的角度來看的。

Maybe both

也許兩者都有

First of all, we have not disclosed the details of the agreement yet, but we'll we'll we'll add more details in our next 20 F, what can I tell you there's some formula over there that is going to build in some minimums, but not in the current point in time. Yes.

首先，我們還沒有透露協議的細節，但我們會在接下來的 20 F 中添加更多細節，我能告訴你的是，那裡有一些公式將內置一些最小值，但不是在當前時間點。是的。

And some percentage, but we don't want to get into this just because the way we structure the agreement is very beneficial.

有一定比例，但我們不想僅僅因為我們建構協議的方式非常有利而介入這一點。

And for us in terms of the way we want to manage our business.

對我們來說，就我們想要管理業務的方式而言。

Okay, fair enough.

好吧，很公平。

I think I think the ball we have related to some of you have to remember that Pizza Pizza, it's a long-term agreement. Well, even though the built-up in agreement in a way that both sides can can execute.

我認為我們舉行的舞會與你們中的一些人必須記住，披薩披薩，這是一項長期協議。好吧，儘管以雙方都可以執行的方式達成了協議。

Okay, got it on. But I think that that's all we have. So we'll see you guys at the Analyst Day next week,

好的，裝上了。但我認為這就是我們所擁有的一切。那我們將在下週的分析師日見到你們，

Thank you

謝謝

Thank you. And this is all the time we have for questions, thus ending the Q&A session. I would now like to turn the conference back to Eric Meltzer for closing remarks.

謝謝。這是我們所有提問的時間，問答環節就這樣結束了。現在我想請艾瑞克‧梅爾策 (Eric Meltzer) 致閉幕詞。

So thank you all for the being with us today and looking forward to see part of you and that the others will be able to hear next week when we have the Investor Day when we're going to have it should then give some colors on on technology on the go to market here in the US and on the operational as well as the some clinical from a management team will present there. So a CEO next week, and thank you for being less than that support of NetIQ's Good day.

因此，感謝大家今天與我們在一起，並期待著見到你們的一部分，其他人將能夠在下週我們舉辦投資者日時聽到，屆時我們應該給它一些色彩管理團隊將介紹在美國上市的技術以及營運方面的技術以及一些臨床成果。那麼下週就成為 CEO，感謝您對 NetIQ 的支持，美好的一天。

As this concludes today's conference call. Thank you all for participating. You may now disconnect and have a pleasant day.

今天的電話會議到此結束。感謝大家的參與。您現在可以斷開連接並度過愉快的一天。